rethinkPeptides Search
Menu
Study breakdown

How a Non-Coding RNA Drives Inflammation in Rosacea Through the Cathelicidin Peptide Pathway

evidence
The takeaway

The long non-coding RNA NEAT1 is overexpressed in rosacea skin and amplifies inflammation by regulating S100A9 expression through a mechanism triggered by the antimicrobial peptide LL-37.

237 differentially expressed lncRNAs

First genome-wide lncRNA profiling of rosacea skin, with NEAT1 identified as a key driver linking cathelicidin peptide LL-37 to inflammatory gene expression

What the researchers found

RNA sequencing of skin from six rosacea patients identified 237 differentially expressed long non-coding RNAs, 38 miRNAs, and 1,784 mRNAs in lesioned vs. non-lesioned skin. NEAT1 was upregulated in both rosacea skin tissue and LL-37-treated HaCaT cells. Knocking down NEAT1 reduced inflammatory damage in vitro. NEAT1 directly interacted with miR-196a-5p, and downregulating miR-196a-5p reversed the anti-inflammatory effects of NEAT1 knockdown on S100A9, confirming the NEAT1/miR-196a-5p/S100A9 regulatory axis.

Why it matters

Rosacea affects millions of people and its molecular mechanisms are poorly understood, making treatment largely symptomatic. The cathelicidin peptide LL-37 has been identified as a key driver of rosacea inflammation, but how it triggers downstream inflammatory cascades was unclear. This study reveals a specific regulatory pathway (NEAT1/miR-196a-5p/S100A9) that connects LL-37 to sustained inflammation, providing potential new therapeutic targets that could interrupt the inflammatory cycle at its source.

How the study worked

Researchers performed genome-wide RNA sequencing on paired lesioned and non-lesioned skin samples from six rosacea patients, analyzing lncRNA, miRNA, and mRNA expression profiles. They identified hub lncRNAs in a competing endogenous RNA (ceRNA) network. In vitro experiments used HaCaT keratinocyte cells treated with the antimicrobial peptide LL-37 to model rosacea inflammation. Gene knockdown (siRNA) of NEAT1 and miR-196a-5p inhibitors were used to validate the regulatory axis.

What this study cannot tell us

The genomic profiling used only six patients, limiting statistical power and generalizability. The in vitro experiments used HaCaT cells (an immortalized keratinocyte line), which may not fully replicate the behavior of primary skin cells or the complex multicellular environment of rosacea skin. The study demonstrates association and a plausible mechanism but does not prove this axis drives rosacea in vivo. No therapeutic intervention was tested in animal models or patients.

How to read the evidence

This is an exploratory molecular study combining RNA sequencing from six patients with in vitro mechanistic validation. While the methodology is sound and the ceRNA network analysis is comprehensive, the small patient sample and lack of in vivo validation limit the strength of the evidence.

When this study was published

Published in 2021, this study is relatively recent. The connection between non-coding RNAs and peptide-mediated skin inflammation continues to be actively investigated.

The bigger picture

This study connects two important areas of dermatological research: the role of antimicrobial peptides (particularly cathelicidin/LL-37) in rosacea pathogenesis and the emerging field of non-coding RNA regulation in inflammatory skin diseases. The finding that LL-37 drives inflammation through a non-coding RNA cascade adds a new layer of complexity to our understanding of peptide-mediated skin inflammation and expands potential intervention points beyond targeting the peptide itself.

Questions still open

  • Could targeting NEAT1 or the miR-196a-5p/S100A9 axis provide a new therapeutic approach for rosacea that is more targeted than current anti-inflammatory treatments?
  • Is the NEAT1/miR-196a-5p/S100A9 axis active in all rosacea subtypes, or is it specific to certain clinical presentations?
  • Do other antimicrobial peptides beyond LL-37 also trigger NEAT1 upregulation in inflammatory skin conditions?

Common questions

What does the antimicrobial peptide LL-37 have to do with rosacea?
LL-37 (cathelicidin) is an antimicrobial peptide normally produced by skin cells to fight infections. In rosacea patients, LL-37 is produced in abnormally high amounts and in forms that trigger intense inflammation — causing the redness, bumps, and irritation characteristic of the condition. This study shows LL-37 drives inflammation partly by increasing levels of a regulatory RNA molecule called NEAT1.
What is a 'competing endogenous RNA' and how does it cause inflammation?
A competing endogenous RNA (ceRNA) is a molecule that acts like a sponge, soaking up microRNAs that would normally keep certain genes in check. In this case, NEAT1 absorbs miR-196a-5p, which normally suppresses the inflammatory protein S100A9. With miR-196a-5p 'sponged up,' S100A9 levels rise unchecked, driving the inflammatory cycle in rosacea skin.

Read the original research

Long non-coding RNA NEAT1 functions as a competing endogenous RNA to regulate S100A9 expression by sponging miR-196a-5p in rosacea.

Journal of dermatological science, 102(1), 58-67

Citation

Wang, Lian; Wang, Yu-Jia; Hao, Dan; Wang, Xiao-Yun; Li, Xiao-Xue; Zhao, Qian; Li, Yan-Mei; He, Gu; Jiang, Xian. (2021). Long non-coding RNA NEAT1 functions as a competing endogenous RNA to regulate S100A9 expression by sponging miR-196a-5p in rosacea.. Journal of dermatological science, 102(1), 58-67. https://doi.org/10.1016/j.jdermsci.2021.02.005